SCHEMBL5490785

SCHEMBL5490785

Cc1ncccc1SC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.34
NOS3 P29474 1/20 0.34
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34
NPC1 O15118 1/20 0.34
HSP90AA1 P07900 1/20 0.34
P2RX7 Q99572 1/20 0.34
GRM5 P41594 1/20 0.33
SLC22A12 Q96S37 1/20 0.33
KDM4E B2RXH2 4/20 0.33
GAA P10253 2/20 0.33
MAPT P10636 2/20 0.33
APOBEC3G Q9HC16 2/20 0.33
MAPK1 P28482 1/20 0.33
HTT P42858 2/20 0.32
HSD17B10 Q99714 1/20 0.32
SLC6A2 P23975 1/20 0.32
AOC3 Q16853 1/20 0.32
CYP2A6 P11509 1/20 0.32
MKNK1 Q9BUB5 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29876001 0.78 L3MBTL1 (0.39) L3MBTL1NOS3NOS1NOS2NPC1
SCHEMBL15413736 0.78 TRIM24 (0.38) L3MBTL1SLC22A12KDM4EHSD17B10AOC3
SCHEMBL18352991 0.78 LMNA (0.37) L3MBTL1GRM5SLC22A12KDM4EHSD17B10
SCHEMBL3074012 0.78 NOS3 (0.47) NOS3NOS1NOS2NPC1HSP90AA1
SCHEMBL5644357 0.76
SCHEMBL27791995 0.75 GRM5 (0.37) L3MBTL1NPC1GRM5SLC22A12KDM4E
SCHEMBL15961557 0.75 KDM4E (0.49) L3MBTL1NPC1HSP90AA1KDM4EGAA
SCHEMBL18353016 0.75 PTPN11 (0.38)
SCHEMBL18526835 0.74 HTT (0.57) L3MBTL1NPC1HSP90AA1KDM4EMAPT
SCHEMBL22766464 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1392653-B1 A SHORT SYNTHESIS OF PYRIDINE-BASED PHARMACEUTICAL INTERMEDIATES WITH SULFUR-CONTAINING GROUPS AT THE 2- AND 3-POSITIONS UNIV NORTH CAROLINA STATE (US) 2007-08-15 EP disclosed
US-6987189-B2 Short synthesis of pyridine-based pharmaceutical intermediates NORTH CAROLINA STATE UNIVERSITY (US) 2006-01-17 US disclosed
US-20050065347-A1 Short synthesis of pyridine-based pharmaceutical intermediates COMINS DANIEL L (US) 2005-03-24 US disclosed
US-6855825-B2 Short synthesis of pyridine-based pharmaceutical intermediates NORTH CAROLINA STATE UNIVERSITY (US) 2005-02-15 US disclosed
CN-1533379-A Small synthesis of pyridine-based pharmaceutical intermediates containing sulfur in the 2-and 3-positions �Ϻ���ͨ��ѧ 2004-09-29 CN disclosed
US-20040138463-A1 Short synthesis of pyridine-based pharmaceutical intermediates COMINS DANIEL L (US) 2004-07-15 US disclosed
US-6706884-B2 REACTING 2-METHYL-3-(TERT-BUTYLTHIO)PYRIDINE DERIVATIVE WITH AMINOALKYL DISULFIDE DERIVATIVE; SULFIDING IN STRONG AMIDE BASE NORTH CAROLINA STATE UNIVERSITY 2004-03-16 US disclosed
EP-1392653-A1 A SHORT SYNTHESIS OF PYRIDINE-BASED PHARMACEUTICAL INTERMEDIATES WITH SULFUR-CONTAINING GROUPS AT THE 2- AND 3-POSITIONS North Carolina State University (US) 2004-03-03 EP disclosed
US-20030166941-A1 Short synthesis of pyridine-based pharmaceutical intermediates COMINS DANIEL L (US) 2003-09-04 US disclosed
US-6534656-B2 Intermediates in manufacture of antibiotic compounds NORTH CAROLINA STATE UNIVERSITY 2003-03-18 US disclosed
US-20020193606-A1 Short synthesis of pyridine-based pharmaceutical intermediates NORTH CAROLINA STATE UNIVERSITY 2002-12-19 US disclosed
WO-2002096878-A1 A SHORT SYNTHESIS OF PYRIDINE-BASED PHARMACEUTICAL INTERMEDIATES WITH SULFUR-CONTAINING GROUPS AT THE 2- AND 3-POSITIONS NORTH CAROLINA STATE UNIVERSITY (US) 2002-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166941-A1 Short synthesis of pyridine-based pharmaceutical intermediates CYP2B6, CYP2D6, CYP2A6 L3MBTL1 4339/4885NOS3 3506/4885NOS1 4290/4885
US-20040138463-A1 Short synthesis of pyridine-based pharmaceutical intermediates CYP2B6, CYP2D6, CYP2A6 L3MBTL1 4339/4885NOS3 3506/4885NOS1 4290/4885
US-20020193606-A1 Short synthesis of pyridine-based pharmaceutical intermediates CYP2B6, CYP2D6, CYP2A6 L3MBTL1 4339/4885NOS3 3506/4885NOS1 4290/4885
US-20050065347-A1 Short synthesis of pyridine-based pharmaceutical intermediates CYP2B6, CYP2D6, CYP2A6 L3MBTL1 4314/4885NOS3 2378/4885NOS1 3657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.